Lilly’s New Weight‑Loss Pill Shows Double the Results of Novo Nordisk’s GLP-1 Rival in a Major Study

Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide

A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it

Lilly’s New Weight‑Loss Pill Shows Double the Results of Novo Nordisk’s GLP-1 Rival in a Major Study

Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.

Novel GLP-1 Pill Tops Oral Semaglutide for Diabetes

(MedPage Today) -- An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ACHIEVE-3 trial showed. Among...

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

Lilly says orforglipron tops Wegovy pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral Wegovy in type 2 diabetes raises as many questions as it answers.

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety...